A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 524,900 shares of ENTA stock, worth $4.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
524,900
Previous 510,900 2.74%
Holding current value
$4.9 Million
Previous $6.63 Million 17.85%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.05 - $16.54 $140,700 - $231,560
14,000 Added 2.74%
524,900 $5.44 Million
Q2 2024

Aug 09, 2024

SELL
$11.43 - $17.02 $173,736 - $258,704
-15,200 Reduced 2.89%
510,900 $6.63 Million
Q1 2024

May 13, 2024

SELL
$10.08 - $17.46 $326,592 - $565,704
-32,400 Reduced 5.8%
526,100 $9.19 Million
Q4 2023

Feb 13, 2024

BUY
$8.18 - $10.78 $821,272 - $1.08 Million
100,400 Added 21.92%
558,500 $5.26 Million
Q3 2023

Nov 14, 2023

SELL
$11.09 - $22.13 $201,838 - $402,766
-18,200 Reduced 3.82%
458,100 $5.12 Million
Q2 2023

Aug 11, 2023

BUY
$20.68 - $39.85 $1.01 Million - $1.95 Million
48,836 Added 11.42%
476,300 $10.2 Million
Q1 2023

May 12, 2023

SELL
$38.82 - $54.59 $1.78 Million - $2.5 Million
-45,736 Reduced 9.67%
427,464 $17.3 Million
Q4 2022

Feb 13, 2023

BUY
$40.77 - $53.73 $212,004 - $279,396
5,200 Added 1.11%
473,200 $22 Million
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $3.61 Million - $5.33 Million
-74,800 Reduced 13.78%
468,000 $24.3 Million
Q2 2022

Aug 12, 2022

SELL
$38.13 - $76.93 $2.45 Million - $4.95 Million
-64,300 Reduced 10.59%
542,800 $25.7 Million
Q1 2022

May 13, 2022

SELL
$56.06 - $74.11 $6.02 Million - $7.95 Million
-107,300 Reduced 15.02%
607,100 $43.2 Million
Q4 2021

Feb 11, 2022

SELL
$60.19 - $97.37 $2.54 Million - $4.11 Million
-42,185 Reduced 5.58%
714,400 $53.4 Million
Q3 2021

Nov 12, 2021

SELL
$41.02 - $58.65 $1.69 Million - $2.41 Million
-41,143 Reduced 5.16%
756,585 $43 Million
Q2 2021

Aug 13, 2021

SELL
$43.76 - $53.11 $4.48 Million - $5.44 Million
-102,472 Reduced 11.38%
797,728 $35.1 Million
Q1 2021

May 13, 2021

SELL
$41.69 - $54.95 $5.57 Million - $7.35 Million
-133,700 Reduced 12.93%
900,200 $44.4 Million
Q4 2020

Feb 10, 2021

BUY
$41.16 - $47.47 $201,683 - $232,603
4,900 Added 0.48%
1,033,900 $43.5 Million
Q3 2020

Nov 13, 2020

BUY
$43.36 - $53.53 $3.73 Million - $4.61 Million
86,100 Added 9.13%
1,029,000 $47.1 Million
Q2 2020

Aug 13, 2020

BUY
$46.37 - $57.58 $2.89 Million - $3.59 Million
62,300 Added 7.07%
942,900 $47.3 Million
Q1 2020

May 14, 2020

BUY
$40.22 - $62.0 $5.99 Million - $9.24 Million
149,000 Added 20.37%
880,600 $45.3 Million
Q4 2019

Feb 13, 2020

BUY
$57.95 - $66.61 $3.98 Million - $4.58 Million
68,700 Added 10.36%
731,600 $45.2 Million
Q3 2019

Nov 13, 2019

BUY
$60.08 - $88.17 $6.77 Million - $9.93 Million
112,600 Added 20.46%
662,900 $39.8 Million
Q2 2019

Aug 12, 2019

SELL
$81.3 - $97.35 $7.74 Million - $9.27 Million
-95,205 Reduced 14.75%
550,300 $46.4 Million
Q1 2019

May 14, 2019

SELL
$69.08 - $105.66 $10.5 Million - $16 Million
-151,695 Reduced 19.03%
645,505 $61.7 Million
Q4 2018

Feb 13, 2019

BUY
$65.41 - $84.65 $52.1 Million - $67.5 Million
797,200 New
797,200 $56.5 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $194M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.